News

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Receives Award from Maryland Stem Cell Research Fund to Support Clinical Study of SBI-101

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Receives Award From Maryland Stem Cell Research Fund to Support Clinical Study of SBI-101 for the Treatment of Acute Kidney Injury Associated with Sepsis

Award to help fund Sentien’s Ph 1/2 clinical study at Maryland sites!

READ PRESS RELEASE >

Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to evaluate Sentien’s ex vivo cell therapy, SBI-101, in patients suffering from acute kidney injury (AKI) associated with sepsis.  This patient population includes COVID-19 patients with sepsis-AKI.

The BARDA-Sentien collaboration will enable evaluation of high dose SBI-101 therapy for the first time and support regulatory path activities to advance its development for the treatment of sepsis.

Read More >

Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19.  SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

In addition, the independent Data Safety Monitoring Board has reviewed the safety data from the first cohort and supports continuation of the study and dose escalation.

Read More >

Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the first subject has been enrolled in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19 at the University of New Mexico (UNM) Hospital.  SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

Read More >

Sentien-Led Team Awarded $2.4M Contract from the U.S. DoD and MTEC

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies-Led Team Awarded $2.4M Contract from the U.S. Department of Defense and the Medical Technology Enterprise Consortium

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, has been awarded a $2.4 million contract from the Medical Technology Enterprise Consortium (MTEC).  The funds will be used to support the development of a potency assay for mesenchymal stromal cells (MSCs) in regenerative medicine products. Read More >

Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19.  Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT). Read More >

Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Dr. Allen Nissenson as Chief Medical Officer

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer.  Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.  Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc. Read More >

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman.  Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team. Read More >

By
In News
Posted

Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien to Present SBI-101 Clinical Data in AKI at 2020 American Society of Gene & Cell Therapy Annual Meeting that Supports Expansion to COVID-19

Sentien’s R&D team will present platform development and clinical data at the American Society of Gene & Cell Therapy Annual Meeting during virtual poster sessions.

Sentien’s SBI-101 clinical data in AKI patients shows immunomodulatory effects consistent with our therapeutic hypothesis and also applicable to COVID-19 patients.

Clinical Evidence for Immune Reprogramming with Extracorporeal Mesenchymal Stromal Cell Therapy

Ex-Vivo Cell Therapy Platform for Immune Reprogramming in Autoimmunity

Load More